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Abstract 
On The Innervation of Salivary Glands and Treatment of Dry Mouth 
- An Experimental and Clinical Study 
Nina Khosravani 
Institute of Odontology, The Sahlgrenska Academy, University of Gothenburg, Box 450, 
405 30 Gothenburg, Sweden 
 
Detailed knowledge of the innervation of the parotid gland is essential in basic studies 
on various neuroglandular phenomena as well as in various types of orofacial 
surgery. The innervation is more complex than usually depicted in Textbooks. Using 
the rat as experimental model, it was shown that not only the classical auriculo-
temporal nerve but also the facial nerve contributed to the cholinergic innervation of 
the gland, and that facial nerve-mediated impulses, reflexly elicited, evoked secretion 
of saliva. In humans, aberrant regenerating parasympathetic nerve fibres of the facial 
nerve may, therefore, be a potential contributor to Frey´s syndrome, characterized by 
sweating and redness over the parotid region. Little is known about the sensory 
innervation of salivary glands. A co-localization of the neuropeptides substance P and 
calcitonin gene-related peptide signals sensory nerve fibres in the salivary glands. 
Though the auriculo-temporal nerve trunk carries sensory fibres from the trigeminal 
ganglion, denervation experiments showed that those sensory substance P- and 
calcitonin gene-related fibres that innervate the gland use other routes. The 
comparison of a number of various types of glands in the ferret revealed large 
differences in the acetylcholine synthesis, the mucin-producing sublingual, zygomatic 
and molar glands showing a synthesizing capacity, expressed per gland weight, 3-4 
times higher than that of the serous parotid gland and the sero-mucous 
submandibular gland, implying a high cholinergic tone in the mucin-producing glands. 
The acetylcholine formation was due to the specific action of choline 
acetyltransferase, and denervation experiments showed this enzyme to be confined 
to the nerves. Thus, no support for an extra-neuronal synthesis of acetylcholine by 
the activity of choline acetyltransferase was found. Dry mouth jeopardizes the oral 
health. A new approach to the treatment of dry mouth was tested in healthy subjects 
and in patients suffering from salivary gland hypofunction. The cholinesterase 
inhibitor physostigmine prevents the breakdown of acetylcholine released from 
cholinergic nerve endings: acetylcholine accumulates and either evokes an effector 
response or enhances it. Physostigmine was applied locally on the oral mucosa 
aiming at activating hundreds of underlying, submucosal minor glands (producing 
lubricating mucin), while at the same time minimising systemic cholinergic effects. A 
dose-finding showed that it was possible to obtain a long-lasting secretion of saliva in 
the two study groups concomitant with a long-lasting relief from oral dryness (as 
revealed by Visual Analogue Scale-scoring) in the group of dry mouth patients at a 
dose level, where side-effects were absent or in the form of mild gastro-intestinal 
discomfort. The local drug application, directed towards the minor salivary glands, 
seems promising and may develop into a therapeutic option in the treatment of dry 
mouth. 
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Introduction 
 
Saliva is of outmost importance for the oral health. It lubricates oral structures, 
maintains neutral pH by its buffering capacity, remineralizes the enamel of the 
teeth, cleanses the oral cavity, exerts antimicrobial effects, stimulates wound 
healing, solutes tastants, aids in maintenance of taste buds, takes part in the 
digestion of the food and protects the oesophageal mucosa from regurgitating 
gastric secretion. Saliva is a mixture of secretion from parotid, submandibular 
and sublingual glands and hundreds of minor salivary glands located just under 
the mucosal epithelium and distributed throughout the mouth. Each type of gland 
contributes to whole saliva with specific constituencies. The daily salivary output 
is approximately one liter and the flow rate varies considerably over time (Dawes, 
1972; Kaplan & Baum, 1993; Tenovou, 1998; van Nieuw Amerongen et al., 2004; 
Flink et al., 2005).  
 
The low mucin-rich salivary flow rate during the night-time is maintained by the 
spontaneous activity of the minor glands. Depending on type and intensity of the 
reflex stimulus different types of glands are thrown into activity to various extent. 
At rest a weak reflex driven secretion, in response to mucosal dryness and 
movements of the lips and the tongue, is superimposed on the spontaneous 
secretion. In response to a meal a number of salivatory reflexes are set up by 
stimulation of mechanoreceptors, gustatory receptors, olfactory receptors and 
nociceptors, and, as a result, large volumes of saliva are secreted from the 
parotid and submandibular glands (Hector & Linden, 1999).  
 
All types of salivary glands and their secretory elements (acini, ducts and 
myoepithelial cells) seem to be supplied with parasympathetic nerve fibres. The 
extent of the sympathetic innervation of the secretory elements varies between 
species and between the glands in the same species. For instance in humans, 
the sympathetic nerve supply of the secretory cells is scarce in the labial glands 
but rich in the submandibular glands. While parasympathetic activity evokes a 
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rich flow of saliva, the response to sympathetic activity is usually small, if any. 
Though both the stimulation of the parasympathetic nerve and the stimulation of 
the sympathetic nerve give rise to protein secretion, the protein concentration will 
be less in parasympathetic saliva as a consequence of the large fluid production 
in response to the parasympathetic innervation. Under physiological conditions 
sympathetic secretory activity is thought to occur during a background of on-
going parasympathetic secretion, and positive interactions may occur with 
respect to fluid and protein output. In contrast, the two divisions of the autonomic 
nervous system have opposite effects on the blood vessels. Sympathetic 
stimulation decreases the blood flow through the gland, while parasympathetic 
stimulation increases the blood flow. However, the sympathetic vasoconstrictor 
fibres are of different origin than the sympathetic secretory fibres. They are not 
part of the alimentary reflexes but are mobilized during a profound fall in arterial 
blood pressure such as that upon massive bleeding (Emmelin, 1967, 1987; 
Garrett, 1988).  
 
Traditionally, acetylcholine is the parasympathetic transmitter and noradrenaline 
the sympathetic transmitter. However, in the late 1970s it became apparent that 
a number of transmission mechanisms besides the classical cholinergic and 
adrenergic ones are at work in the neuro-effector region of various autonomically 
innervated organs. Atropine-resistant parasympathetic vasodilatation is a well-
known phenomenon in salivary glands, first demonstrated by Heidenhain in 
1872. Retrospectively, the observation of Heidenhain is the original 
demonstration of a so called parasympathetic non-adrenergic, non-cholinergic 
effector response (Burnstock, 1986).  The phenomenon was once explained by 
the so-called “proximity-theory”, i.e. the contact between nerve-ending and 
postjunctional receptors was too tight to allow the access of atropine (see Bloom 
& Edwards, 1980). The parasympathetic atropine-resistant vasodilatation is 
presently attributed to a number of neuropeptides, notable vasoactive intestinal 
peptide, and to nitric oxide (Edwards, 1998).  
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Over more than hundred years, the parasympathetic nerve-evoked flow of saliva 
has been thought to be completely abolished by atropine, a finding that has been 
interpreted to imply that acetylcholine is the sole transmitter in parasympathetic 
nerve-evoked secretion. When shifting focus from classical laboratory animals, 
such as the cat and the dog, to the rat, an atropine-resistant parasympathetic 
salivary secretion from the submandibular gland was reported, in passing, by 
Thulin (1976a) when studying the atropine-resistant blood flow of this gland.  
Though not immediately recognized at that time, the observation made by Thulin 
became the beginning of a paradigm shift (Ekström et al., 1983; Ekström, 
1999a).  A number of parasympathetic peptidergic transmission mechanisms 
were found to release proteins or, in addition, to evoke fluid secretion and further, 
to interact positively with each other and with acetylcholine. Moreover, 
parasympathetic non-adrenergic, non-cholinergic transmitters are involved in 
gland metabolism and gland growth. In the exploration of the field of the 
regulation of salivary glandular activities by parasympathetic non-adrenergic, 
non-cholinergic transmission mechanisms not only the rat but also the ferret 
became useful experimental animals (Ekström et al., 1988b). Like the glands of 
the rat, those of the ferret responded with secretion of saliva to neuropeptides, 
administered to the blood stream, and with an atropine-resistant flow of saliva to 
parasympathetic stimulation. Non-adrenergic, non-cholinergic mechanisms were 
also found to act in those glands of the cat and the dog, favoured by the early 
experimenters in physiology, where no overt secretion of fluid is observed after 
atropinization in response to parasympathetic nerve stimulation; here, the non-
adrenergic, non-cholinergic transmission mechanisms evoked exocytosis of 
secretory granules and protein secretion (Ekström, 1999a). 
 
The acinar cells of salivary glands are supplied with muscarinic receptors, usually 
of both muscarinic M1 and M3 subtypes (Tobin et al., 2009). The adrenergic 
receptors are also usually of two types, α1 and β1 (Baum & Wellner, 1999). In 
addition, the acinar cells may be supplied with various receptors for the 
peptidergic transmitters, involving vasoactive intestinal peptide, pituitary 
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adenylate cyclase activating peptide, substance P, neurokinin A, calcitonin gene-
related peptide and neuropeptide Y (Ekström, 1999a).   
 
Intracellularly, the various transmitters acting on the receptors of the acinar cells 
mobilize either Ca2+/Inositoltriphosphate or cAMP. For example, stimulation of 
muscarinic, α1-adrenergic and substance P-ergic receptors activate the 
Ca2+/Inositoltriphosphate- pathway, while β1-adrenergic and vasoactive intestinal 
peptide-ergic receptors activate the cAMP-pathway.  In addition, agonists 
mobilizing the cAMP-pathway do also generate nitric oxide by the activity of 
neuronal type of nitric oxide synthase (but of non-nervous origin). cAMP/nitric 
oxide causes the secretion of protein with little accompanying fluid, while 
Ca2+/Inositoltriphosphate does also cause secretion of protein but which, in this 
case, is accompanied with a large amount of fluid (Baum & Wellner, 1999; 
Ekström et al., 2007). 
 
The fluid secretion is an active, energy-dependent, process that requires an 
adequate blood flow. Upon increase in intracellular Ca2+, basolateral K+ - and 
apical Cl– -channels open and the two electrolytes move down their 
concentration gradients to the extracellular compartment.  Cl- in the acinar lumen 
will drag Na+ from the interstitium to the lumen, and the luminal increase of NaCl 
creates an osmotic gradient that causes large volumes of water to move into the 
lumen. During its passage through the ducts, the electrolyte composition of the 
primary saliva is modified and further, proteins are added but the volume of 
saliva is not affected, resulting in a hypotonic secondary saliva (Poulsen, 1998). 
Proteins of acinar and ductule cells are secreted by two main routes, the 
regulated exocytotic route, involving storage granules, and the constitutive 
vesicular route, involving a direct secretion from the Golgi (Proctor, 1998). Acini 
and ducts are embraced by myoepithelial cells, increasing - by their contraction - 
the intraluminal pressure that may be of particular importance for the flow of the 
viscous mucin-rich saliva (Garrett & Emmelin, 1979). The myoepithelial cells are 
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activated both by muscarinic and α1-adrenergic stimuli and, in addition by 
tachykinins (as shown by physalaemin, Thulin, 1976b).   
 
Little is known about the sensory innervation of salivary glands. In general, 
nerves showing co-localization of substance P and calcitonin gene-related 
peptide are usually thought to be of sensory origin (Saria et al., 1985). Though 
calcitonin gene-related peptide-containing nerve fibres may occur close to acinar 
cells in the rat parotid gland, most of these fibres are found around secretory 
ducts and blood vessels and these fibres contain substance P in addition. The 
bulk of the calcitonin gene-related peptide /substance P-containing nerve fibres is 
of sensoric origin, since they are destroyed by the sensory neurotoxin capsaicin. 
Most substance P-containing nerve fibres are devoid of calcitonin gene-related 
peptide and found close to acini (Ekström et al., 1988a, 1989). Calcitonin gene-
related peptide and substance P are found in both the trigeminal ganglion and 
the otic ganglion (Ma et al., 2001; Hardebo et al., 1992). Another neuropeptide of 
the parotid gland, vasoactive intestinal peptide, which cause a small, protein rich, 
flow of saliva, is only localized in the otic ganglion (and not in the trigeminal 
ganglion, Hardebo et al., 1992). The auriculo-temporal nerve is not only 
conveying secreto-motor fibres for the parotid gland but also sensory nerve fibres 
from the trigeminal ganglion to the temporal region, auricle, external acoustic 
meatus, tympanic membrane and temporo-mandibular joint (Greene, 1955; Gray, 
1988). Thus, there is the possibility that the auriculo-temporal nerve trunk 
innervates the parotid gland not only with nerve fibres from the otic ganglion but 
also with nerve fibres of the trigeminal ganglion.  
 
Nerves do not only exert short-term regulation of the salivary glands but they also 
exert a long-term regulation of gland metabolism and gland size (Ohlin, 1966). 
Moreover, by their transmitter bombardement of the glandular receptors over 
time the nerves are of importance for the sensitivity of the glandular receptors 
(Emmelin, 1965, see below). 
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Whereas a long-term endocrine influence on salivary gland size and function is a 
well-recognized phenomenon, exemplified with the development of dry mouth in 
post-menopausal women (Johnson, 1988; Eliasson et al., 2003), hormones are 
not usually thought to take part in the immediate regulation of the secretory 
activity of the glands (Emmelin, 1967; Johnson & Gerwin, 2001; Ferguson, 
1999). Recent animal experiments do, however, show the gastro-intestinal 
peptide hormones cholecystokinin, gastrin and melatonin to secrete proteins from 
the parotid glands of rats in vivo without any accompanying overt fluid secretion 
(Çevik Aras & Ekström, 2006, 2008), in analogy to the action of some 
parasympathetic neuropeptides (Ekström, 1999a).  
 
Acetylcholine and its synthesizing enzyme, choline acetyltransferase - 
transferring the acetylgroup from acetylCoenzyme A to choline, is traditionally 
associated with nervous structures. The placenta of higher primates is the 
unambiguous example of a non-nervous synthesis of acetylcholine, since this 
tissue lacks an innervation (Hebb & Ratković, 1962). In recent years, a non-
nervous acetylcholine synthesis has come in focus (Wessler & Kirkpatrick, 2008; 
Kawashima &  Fujii, 2008). A number of epithelial, endothelial, mesenchymal and 
immune cells are reported to show immunoreactivity for choline acetyltransferase 
and to contain acetylcholine.  Among the many functions attributed to non-
neuronal acetylcholine are skin regeneration, wound healing, airway ciliary 
activity, blood flow control, antibody generation and inhibition of release of pro-
inflammatory mediators. In the context of the present Thesis, it may also be 
noted that non-neuronal acetylcholine is implied in modifying fluid and electrolyte 
movements in mucosal and glandular epithelial cells of the airways and in 
increasing paracellular permeability in the pancreas by an action on tight 
junctions. The demonstration of acetylcholine synthesis in a number of tissues 
raises the question whether in some of these tissues “contaminating” cholinergic 
nerves are present. In homogenates of denervated skeletal muscles, a capacity 
to synthesize acetylcholine of 5-8% remains. This persisting synthesis is due to 
an unspecific synthesis of acetylcholine by extraneuronal carnitine 
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acetyltransferase (Tuček, 1982). Of anatomical reasons studies on 
parasympathetically denervated structures are few. The pathways of the 
postganglionic nerves may in part be unknown or the location of the relay 
between pre- and postganglionic nerves not easily accessible. In fact, in most 
cases the ganglia are located within the organ. The urinary bladder of the male 
rat and the parotid gland belong to those structures where the respective 
ganglion is situated outside the effector organ.  
 
Though the parotid gland has been used as neurobiological model organs since 
the days of Claude Bernard, for example to study various denervation 
phenomena such as supersensitivity, no studies have been made on the otic 
ganglionic connection with the gland. By studies of Holmberg (1971, 1972), the 
anatomical routes for the parasympathetic innervation of the dog´s parotid gland 
were shown to include not only the auriculo-temporal nerve but also nerve fibres 
reaching the gland via the internal maxillary artery. Twigs of the facial nerve 
transverse the parotid gland and in the dog´s parotid gland this nerve seems to 
contribute to the secretory response of the gland (Ekström & Holmberg, 1972).  
Knowledge of the parotid innervation is not only of interest to the experimenter 
but must also be of major interest for the oro-facial surgeon. 
 
Frey´s syndrome, also called the auriculo-temporal syndrome or gustatory 
sweating, named after the Polish neurologist Lucja Frey, who was the first to 
identify the role of the auriculo-temporal nerve (1923) in a syndrome 
characterized by sweating, redness, flushing and warming over the parotid region 
in connection with eating.  However, the first case report may be that of 
Kastremsky in 1740, describing a patient with perspiration when eating salty 
food, though the report by Duphenix in 1757 is usually considered as the first 
case of gustatory sweating (Dunbar et al., 2002). Both the patient of Duphenix 
and of Frey had been injured by a bullet penetrating the parotid gland, followed 
by chronic inflammation. Frey´s syndrome is most frequently observed after 
parotid gland surgery, the incidence varying between 3% and 98%, neck 
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dissection, blunt trauma to the cheek and chronic infection of the parotid area. It 
appears over a period of several months. Frey´s syndrome is thought to reflect 
an aberrant regeneration of postganglionic (cholinergic) parasympathetic fibres of 
the auriculo-temporal nerve innervating sweat glands and skin vessels following 
loss of the sympathetic postganglionic (cholinergic) innervation. It may also be 
noted that Frey´s syndrome has been reported in infants as sequale to forceps 
delivery (Johnson & Birchall, 1995). Medical treatment includes topical facial 
application of anticholinergics and botulinum toxin. Surgical treatments include 
division of the branches of the tympanic plexus (Sood et al., 1998; de Bree et al., 
2007). 
 
When the amount of a drug required to evoke a certain (submaximal) biological 
response diminishes the tissue is referred to as being supersensitive. 
Postjunctional supersensitivity is non-specific and develops over a period of 
some weeks. Salivary glands have been useful model organs in exploring the 
phenomenon of supersensitivity, particularly that following interference with the 
parasympathetic innervation (Emmelin, 1961, 1965). It is more marked after 
postganglionic denervation than after preganglionic denervation, since after 
postganglionic denervation the target cells has lost the transmitter 
bombardement not only of that fraction continuously released from the 
postganglionic nerve endings but also of that fraction released upon the arrival of 
the reflexly elicited nerve impulses. Sensitization may be used as a diagnostic 
test for nerve damages (Lapides et al., 1962). For experimental purposes a 
presumptive secretory nerve may be caused to degenerate to allow the 
development of supersensitivity to mark a functional influence of that nerve on 
the secretory cells. 
 
In the clinic, salivary flow rate is categorized as resting/unstimulated (i.e. 
spontaneous secretion combined with a low-graded reflex secretion) and 
stimulated (reflexly elicited by chewing or citric acid). An unstimulated flow rate of 
whole saliva < 0.1 ml/min and a stimulated flow rate of whole saliva < 0.7 ml/min 
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are considered to reflect salivary gland hypofunction (Ericsson & Hardwick, 
1978). Xerostomia is the subjective feeling of dryness of the oral mucosa. 
Xerostomia and salivary gland hypofunction may or may not be related (Fox et 
al., 1987). The term “dry mouth” refers to the subjective feeling of dryness with or 
without demonstration of hyposalivation. The prevalence of dry mouth is 15-40%, 
and is more common among women than men and increases with age 
(Österberg et al., 1984; Nederfors et al., 1997). With a dry mouth, mastication, 
swallowing and speaking become difficult. Taste acuity weakens and oral 
mucosal infections, dental caries and halitosis are common. The quality of life is 
dramatically impaired (Ship et al., 2002; Wärnberg et al., 2005). Among known 
causes of dry mouth are chronic gland inflammation (e.g. Sjögren´s syndrome), 
diabetes, depression, head and neck radiotherapy, radioiodide therapy, 
HIV/AIDS, orofacial trauma, surgery and use of medications (Grišius & Fox, 
1988). In about 20% of those complaining of dry mouth, the cause is unknown 
(Longman et al., 1995; Field et al., 1997). 
 
The options to treat dry mouth are limited and often focused on flavored gums 
and lozenges, artificial saliva, oral rinses and oral gels. These treatments are of 
short duration. A number of drugs for systemic treatments have been suggested 
such as parasympathomimetics, cholinesterase inhibitors, anethole trithione - a 
bile-stimulating agent, bromhexine and guafensin – both mycolytic agents and 
further, the immune-enhancing substance alpha interferon, the cytoprotective 
amifostine, the antimalarial hydroxychloroquine. In many cases, definite clinical 
effects have not been established and further, the use of some of these drugs is 
associated with serious adverse effects. The parasympathomimetic drugs 
pilocarpine (Salagen®) and cevimeline (Evoxac®) are commercially available but 
a number of side effects are observed. In addition, positive results have been 
reported with the use of acupuncture but further clinical trials seem necessary 
(Fox, 2004). A device mounted on an intra-oral removable appliance to stimulate 
the lingual nerve to evoke secretion is presently under clinical trial (Strietzel et 
al., 2007). 
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The amount of acetylcholine continuously released from the cholinergic nerve 
endings in the salivary glands, in the absence of nerve impulse traffic, is 
subliminal for evoking secretion of saliva. It may, however, be revealed by the 
intraductal injection of an acetycholinesterase inhibitor, which prevents the 
degradation of released acetylcholine, and thus,  accumulated acetylcholine in 
the neuro-effector region reaches suprathreshold levels for evoking secretion as 
demonstrated in parotid and submandibular glands (Emmelin et al., 1954; 
Ekström & Emmelin, 1974a,b). Likewise, during on-going nerve stimulation, the 
cholinergic secretory response will be enhanced by a cholinesterase inhibitor 
(Månsson & Ekström, 1991). 
 
Cholinesterase inhibitors may be divided into two groups, reversible and 
irreversible inhibitors. War gases and pesticides are found in the group of 
irreversible inhibitors. The classical reversible inhibitor is physostigmine, also 
called eserine. It is an alkaloid, originally extracted from the Calabar bean of a 
plant growing in West Africa. Physostigmine is a tertiary amine with lipohilic 
properties that readily passes biological barriers (Taylor, 1996). Therefore, it has 
been considered as a therapeutic option in the treatment of Alzheimer’s disease 
(Nordberg & Svensson, 1998). Synthetic congeners of physostigmine are the 
quaternary ammonium derivates neostigmine and pyridostigmine, which exert 
more long-lasting actions but are poorly absorbed. Neostigmine and 
pyridostigmine are made use of clinically, neostigmine to reverse the paralytic 
action of non-depolarising neuromuscular-blocking and to lower the intra-ocular 
pressure and pyridostigmine to enhance the neuro-muscular cholinergic 
transmission in myasthenia gravis.  
 
As mentioned above, the pharmacological treatment of dry mouth involves the 
systemic administration of drugs aiming at activating the parotid and 
submandibular glands. Since it is the mucin-rich saliva rather than the watery 
saliva that protects the oral mucosa from dryness (Collins & Dawes, 1987; 
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Sreebny & Broich, 1988) a therapeutic approach to the treatment of dry mouth 
would be to selectively activate the mucin-producing minor glands located just 
below the oral epithelium. By local application of the drug onto the mucosa, 
followed by the diffusion of the drug through the mucosal barrier, systemic effects 
would be kept at a minimum. In the development of such a treatment, the ferret 
submucosal glands have served as model organs.  Both in humans and in the 
ferret, local application of physostigmine on the mucosa causes the underlying 
submucosal glands to secrete (Hedner et al., 2001; Ekström & Helander, 2002). 
 
The first division of this Thesis focuses on the cholinergic and peptidergic 
innervation of the rat parotid gland with special emphasis on the effect of otic 
ganglionectomy, reflex secretion, the secretory role of the facial nerve and the 
sensory innervation.  In the second division, comparisons are made between 
mucin-producing salivary glands and the serous/seromucous producing glands of 
the ferret with respect to the acetylcholine-synthesizing capacity, secretory 
capacity, cholinergic receptor populations and gland contents of some 
neuropeptides with particular focus on the zygomatic gland. The third division is 
devoted to neuronal and non-neuronal acetylcholine synthesis in salivary glands 
studied in denervation experiments and by the inhibition of choline 
acetyltransferase activity. Finally, the fourth and fifth divisions deal with the 
secretory effect of physostigmine topically applied in healthy subjects and in 
patients suffering from dry mouth including objective measurements of salivary 
secretion and subjective measurements of the feeling of mouth dryness by the 
use of a Visual Analogue Scale. 
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To summarize, the specific aims of this Thesis are to define: 
 the otic ganglionic connections with the parotid gland 
 the secretory role of the facial nerve for the parotid gland 
 the contribution of the auriculo-temporal nerve to the sensory innervation 
of the parotid gland 
 characteristic features of mucin-producing and water-producing salivary 
glands 
 neuronal and non-neuronal acetylcholine synthesis in salivary glands 
 the role of physostigmine as a potential drug for the treatment of dry 
mouth. 
 
 
Material and Methods 
 
Observations on animals 
 
Adult ferrets and Sprague-Dawley rats (B & K Universal, Sollentuna, Sweden) 
were used. The animal experiments were approved by the Local Animal Welfare 
Committee. To perform preliminary surgery the animals were anaesthetized with 
sodium pentobarbitone (25-30 mg/kg I.P.) combined with ketamine (50 mg/kg 
I.M.). Postoperatively, they were given bupvenorphine (0.015 mg/kg S.C.) as an 
analgesic. In acute experiments, the animals were anaesthetized with sodium 
pentobarbitone (50-55 mg/kg I.P. - further anaesthetic was injected I.V. as 
required). During anaesthesia the body-temperature, measured by a rectal 
probe, was maintained at 37.5- 38°C using a thermostatically controlled blanket. 
Drugs were injected intravenously. Under deep anaesthesia, the aorta was cut 
and the animals were killed by exsanguination. The glands were rapidly 
removed, cleaned, and briefly dried on filter paper, weighed and stored at -70 °C 
until analyzed.  
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Preliminary surgery 
The denervation procedures were performed 7-9 days (1,2,3) or 2-3 weeks (2,4) 
before the acute experiment. In rats, the auriculo-temporal nerve was either cut 
where it emerges from the base of the skull or avulsed by swiftly pulling out a 
hook placed under the nerve trunk (taking care to avoid damage to the chorda 
tympani nerve) aiming at parasympathetic (postganglionic) denervation. The 
parasympathetic otic ganglion, located in the oval foramen (Al-Hadithi & Mitchell, 
1987), was extirpated. The facial nerve was cut at the level of the stylomastoid 
foramen and the great auricular nerve was cut where it emerges along the 
posterior border of the sternocleidomastoid muscle. The various types of surgery 
were combined in some series of experiments (1,3). In ferrets, the auriculo-
temporal nerve was avulsed, where it emerges from the base of the skull. The 
buccal branch of the mandibular nerve was approached from the mouth and cut 
as it appears between the pterygoid muscles. Following surgery the wounds 
were sutured. 
 
Duct preparation 
The parotid duct was exposed by a skin incision in the cheek close to the mouth 
in rats (1,2) and ferrets (4). In ferrets, the submandibular duct was exposed in the 
neck (Ekström et al., 1988b).  The lateral duct of the zygomatic gland, draining 
80% of the gland (Ekström & Helander, 2002), was cannulated from the mouth. 
The ducts were cannulated with polyethylene tubes.  
 
Stimulation of nerves 
In rats (1), the facial nerve was exposed at the level of the stylomastoid foramen, 
ligated and cut. The great auricular nerve was exposed as it emerged at the 
posterior border of the sternocleidomastoid muscle, ligated as far from the gland 
as possible and cut. The peripheral end of each nerve was passed trough a ring 
electrode and stimulated at high frequency (40 Hz) using varying voltage (2-8 Hz) 
and time periods of stimulation (2-10 min).  In ferrets (4), the buccal nerve was 
dissected as it appears between the ptergoid muscles. The auriculotemporal 
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nerve was dissected medial of the mandible. The chorda-lingual nerve was 
dissected as far as possible from the submandibular duct. Each nerve was 
ligated and cut. The peripheral nerve end was stimulated with a ring electrode at 
20 Hz (6-8V) either intermittently in periods or continuously up to 80 min.  
 
Reflex secretion 
In rats, the parotid ducts on both sides were cannulated with a fine polyethylene 
catheter (1). About 2-3 hours after surgery, when the animal was awakening and 
licking could be evoked, ascorbic acid was applied on the apex of the tongue 
every 30 s for 10 min, followed by a pause of 10 min and then, a new stimulation 
period of 10 min. Before the start of the application of ascorbic acid, the α-
adrenoceptor blocker phentolamine and the β-adrenoceptor blocker propranolol 
were administered via the cannulated tail vein. When appropriate, the second 
stimulation period was, in addition, performed in the presence of the muscarinic 
receptor blocker metylscopolamine. 
 
Collection of saliva 
Saliva secreted was collected on preweighed filter paper or in ice-chilled 
preweighed tubes, which were then reweighed. The amount of saliva secreted 
was expressed in µl; the specific density was taken to be 1.0 g/ml.  In some 
experiments the amount secreted was related to unit time per gland weight.  
 
Acetylcholine synthesis 
Usually tissues were homogenized in 1 ml of ice-chilled Na-phosphate buffer 
0,05 M, PH 6,5, containing NaCl 200 mM, dithiotreitol 1,2 mM and 0,5% Triton, 
100-X using an Ultra-Turrax homogenizer for 20 s at high speed. In case of 
nervous tissue a Potter-Elvehjem all-glass homogenizer was used. The 
homogenates were frozen and thawed before they were centrifuged (5min, 3000 
x g). The supernatant were transferred to Eppendorf®-tubes and stored at -20 °C 
before being analysed. Briefly, the incubation occurred under optimal conditions, 
and the medium was that of Banns et al. (1979) but dithiotreitol was omitted; the 
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control incubation contained acetylcholinesterase instead of the cholinesterase 
inhibitor physostigmine (eserine). The reaction was started by the addition of 10 
µl [3H]- acetylcoenzyme A (specific activity 180 mCi mmol -1 ) and after 30 min at 
39 °C it was stopped by transferring the incubate to glass tubes containing 2 ml 
of an ice-cold mM acetylcholine chloride, followed by cooling on ice. 
Acetylcholine was extracted using tetraphenylboron (Fonnum, 1969). To 
separate the organic and aqueous phases, the tubes were centrifuged. A sample 
of the organic layer was transferred into scintillaion vials and measured in 
scintillation liquid. The salivary gland homogenate does not only form 
radiolabelled acetylcholine but also radiolabelled acetylcarnitine (Banns et al., 
1979; Banns & Ekström, 1981). The true reading for acetylcholine formation was 
obtained by subtracting the radioactivity left in the control incubation, where 
acetylcholine was continually destroyed by acetylcholinesterase, from that 
obtained in test incubations, where acetylcholine was preserved by eserine. The 
acetylcholine formed (1,2,4) was expressed in nmol per gland per hour or in 
terms of concentration in nmol per 100 mg wet gland tissue. Unless otherwise 
stated, the acetylcholine synthesis is expressed per gland in the text. 
 
Effects of the choline acetyltransferase inhibitor bromoacetylcholine  
To find out whether the acetylcholine synthesis in normally innervated and in 
chronically denervated glands as well as in intact nerves was due to choline 
acetyltransferase activity, the choline acetyltransferase inhibitor 
bromoacetylcholine (0.02–2000 µM, final concentration) was included in the 
incubate (Henderson & Sastry, 1978). The inhibitor was added to the 
homogenate before other components of both test and control medium (1,2,4).  
 
Immunoblotting 
Pieces of gland tissue were homogenized on ice. Gel electrophoreses was used 
to separate proteins. The proteins were then transferred to a membrane (PVDF, 
Hypobond-P, Amersham Bioscience), where they were probed using antibodies 
(primary rabbit polyclonal antibodies, anti subtype M1, M2, M3, M4 and M5, 
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respectively diluted 1:1000 (Santa Cruz Biotechnology). To visualize the proteins 
alkaline phosphates-conjugated secondary goat anti-rabbit antibody (diluted 1:40 
000, Tropix). To exclude unspecific binding, membranes were not exposed to 
primary antibodies. Semi-quantitative measurements of proteins were made by 
densitometry (4). 
 
Measurements of neuropeptide gland contents  
Antiserum raised against synthetic rat calcitonin gene related peptide conjugated 
to bovine serum albumine, was used (4). The antiserum does not recognize 
calcitonin, vasoactive intestinal peptide, somatostatin, gastrin-releasing peptide, 
enkephalins or tachykinins. Antiserum directed against the C-terminal part of 
Substance P was used. The antiserum does not cross-react with other known 
tachykinins. The antiserum recognizes the N-terminal 15-amino acid sequence of 
vasoactive intestinal peptide and does not cross-react with peptidine histidine 
isolucine amide or any known regulatory peptide (Ekström et al., 1984) 
 
Observations on humans 
 
The studies took place at the Department of Cariology, Institute of Odontology, 
Sahlgrenska Academy at Göteborg University. The protocols were reviewed and 
approved by the Ethics Committee at Göteborg University. The studies were 
performed with the signed consent of the participants. The subjects were free to 
discontinue their participation in the studies.  
 
Study 1- Healthy subjects 
Seven healthy female volunteers took part; six were aged between 18 and 24, 
whilst one was 53 years old (5). The mean age was 27 years. The volunteers did 
not experience mouth dryness. They produced a normal salivary flow in response 
to paraffin-chewing (>1ml/min for whole saliva).  
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Study design 
The subjects were treated on four separate days with a spray solution of either 
placebo or physostigmine in various concentrations to the oral mucosa in three 
puffs, one puff in each cheek and one puff under the lip given by the staff. The 
mean weight of the solution sprayed was 166 ± 3 mg (n=28). The total amount of 
physostigmine, as base, administered at three different concentrations was 0.9 
mg (0.5%), 1.8 mg (1.0%) and 3.6 mg (2%). After administration of placebo and 
physostigmine, the subjects were asked to roll their tongues along booth cheek 
surfaces to distribute the solution more effectively on the mucosa. Physostigmine 
has a bitter taste. A grapefruit-like taste correction was therefore made for both 
placebo and physostigmine to minimize the difference in taste between the 
solutions. 
 
Collection of saliva 
Whole saliva secretion was measured every 15 min up to a maximum of 3 hours 
by placing one pre-weighed dental roll in each lower jaw vestibulum for 5 min 
(10-15 min, 25-30 min, 40-45 min, etc). The dental rolls were then weighed to 
calculate the amount of absorbed saliva. The administration of physostigmine/ 
placebo was preceded by a period of 35 min, during which saliva was collected 
three times as above; the amount collected during the period “-5 min to 0 min” 
was set to basal value. 
 
Safety assessment 
The subjects were asked to report any discomfort. 
 
Study 2 - Dry mouth patients 
The study group comprised of twenty volunteers, eleven females and nine males 
(6). The age varied between 24 and 70 years, the mean age being 58 years. The 
subjects had experienced mouth dryness for at least six months prior to 
screening. All subjects were able to secrete but their resting secretion was less 
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than 0.1 ml/min, indicating hyposecretion. Intra-oral examination showed a dry 
mucosa. 
 
Study design 
This study comprised of two phases, A and B. In Phase A, the subjective feeling 
of mouth dryness was assessed by a Visual Analogue Scale. As a result of the 
Visual Analogue Scale-scoring and safety assessment, a dose of physostigmine 
was selected to objectively measure the amount of saliva secreted (Phase B). 
Physostigmine solutions, in a gel formulation, were prepared in a standard 
volume of 300 ul, which was dosed, by the staff, in two equal portions (150 ul) 
inside the upper and lower lips, respectively. The subjects were asked to 
distribute, with the tongue, the solution and to retain it in the mouth. The placebo 
solution was prepared in an identical volume as physostigmine and administered 
in the same manner as physostigmine. Also in this study, a grapefruit-like taste 
correction was made for both placebo and physostigmine. 
 
Phase A 
In phase A, physostigmine (0.9 mg, 1.8 mg, 3.6 mg and 7.2 mg) and placebo 
were compared.  Three different doses of physostigmine or placebo and two 
doses of physostigmine were administered to each subject according to a 
randomisation schedule. At each treatment visit, subjective assessments were 
done at 15 min and 0 min before administration of physostigmine/placebo, and 
again at 15, 30, 60, 90, 120 and 180 min after administration. At each time point, 
the subjects were first asked to estimate the feeling of dryness in the mouth and 
then to estimate the feeling of dryness on the inside of the lips by the questions 
“How do you feel in the mouth right now” (“Hur känner du dig i munnen nu”) and 
“How do you feel on the inside of the lips right now” (“Hur känner du dig på 
läpparnas insida nu”), respectively. The subjects answered by using a Visual 
Analogue Scale. The subject was not allowed to see the immediate preceding 
scores. The answers were documented, by the subject, with one pencil mark 
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across a 100 mm horizontal line that was marked at its extreme end with 
“Extremely dry” (“Extremt torr”) and “Not at all dry” (“Inte alls torr”) 
 
Phase B 
Physostigmine 1.8 mg was selected for the quantative measurements of 
salivation. Pre-weighed dental rolls were placed in the vestibulum of the lower 
jaw on both sides and left to absorb saliva for 15 min.  Before application of the 
study drug or placebo, rolls were applied at 30 min and at 15 min, respectively. 
The volume obtained between -15 min and 0 min was set to basal value.  After 
the application of the drug or placebo, rolls were placed again at 15, 45, 75, 105 
and 165 minutes.  
 
Safety assessment 
Signs of systemic effects were recorded both in Phase A and Phase B and were 
focused on bradycardia, fall in blood pressure, change in mental alertness 
(sedation, nervousness), respiratory distress (asthma), gastro-intestinal 
discomfort (nausea, stomach pain) and excessive sweating. Heart rate and blood 
pressure were measured automatically.  
 
Evaluation - study 2 
The material with respect to the objective measurement of saliva volumes and 
the subjective estimation of oral dryness was analysed “per protocol”. 
 
Statistics 
 
Statistical significances of differences were calculated either by Student´s t-test 
for paired or unpaired values, one-way analysis of variance (ANOVA) followed by 
Fisher´s protected least-significant difference,  Wilcoxon´s signed-rank test for 
paired comparisons or Wilcoxon´s rank-sum test for unpaired comparisons using 
Statview™ SE+. The area under the curve was calculated using KaleidaGraph 
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version 3.51. Probabilities of less than 5% were considered significant. Values 
presented are means ±S.E.M.  
 
Substances 
 
Acetylcholinesterase type V-S, atropine sulphate, bromoacetylcholine bromide, 
hexamehonium, methacholine, methylscopolamine, physostigmine (eserine), 
propranolol were from Sigma. Physostigmine base (to be applied in humans) was 
from Lonza.  Radiolabelled acetylCoenzyme A was from Amersham. 
Phentolamine mesylate was from Novartis Pharma.  
 
 
Results and Discussion 
 
Observations on animals 
 
I. On the innervation of the rat parotid gland 
 
1. Acetylcholine synthesis and Gland weights 
(a) The otic ganglion and the auriculo-temporal nerve  
Otic ganglionectomy reduced the total acetylcholine synthesizing capacity of the 
parotid gland by 88% and the gland weight by 33%, when examined 7 days 
postoperatively (1). In response to division of the auriculo-temporal nerve the 
effect was less conspicuous, the acetylcholine synthesis being reduced by 76% 
and the gland weight by 20%. Avulsion of the auriculo-temporal nerve was more 
effective than otic ganglionectomy with respect to the acetylcholine synthesis 
(94%), while the effect on the gland weight was about the same as after 
ganglionectomy (39%). Acetylcholine synthesis and gland weights of 
contralateral, unoperated glands were unchanged.  
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(b) The facial nerve  
Seven days after division of the facial nerve, the total acetylcholine synthesizing 
capacity of the parotid gland was reduced by 15%, whereas the gland weight 
was unaffected (1). The decrease in the synthesizing capacity upon otic 
ganglionectomy (88%) was even more reduced in combination with facial nerve 
division (98%). Also the combined division of the auriculo-temporal nerve and the 
facial nerve caused a greater fall in the acetylcholine synthesis (89%) than 
division of just the auriculo-temporal nerve (76%). 
 
(c) The great auricular nerve 
Neither the acetylcholine synthesis nor the gland weight was affected by division 
of the great auricular nerve (1).  
 
(d) The distribution of the acetylcholine synthesizing capacity  
In the normally innervated parotid glands the concentration of acetylcholine 
synthesis was evenly distributed in the three lobes of the gland. Otic 
ganglionectomy reduced the synthesizing capacity in all three lobes to the same 
extent. Combined with facial nerve division a further even distributed reduction 
was observed in all three lobes, suggesting that the facial nerve reaches the 
whole gland (1). 
 
2. Reflex secretion 
Reflex secretion was elicited after elimination of the influence of sympathetic 
noradrenaline and circulating catecholamines on the secretory cells (1). Citric 
acid evoked a high flow of saliva from innervated glands, which was not affected 
by interference with the nervous secretory pathways on the contralateral side, 
suggesting that the glands were exposed to maximal secretion.  After acute otic 
ganglionectomy, the flow rate of the denervated gland was reduced by as much 
as 99%. Just division of the auriculo-temporal reduced the flow rate by 88% and 
combined with division of the facial nerve by 95%. The reduction in flow rate 
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(99%) in response to avulsion of the auriculo-temporal nerve was of the same 
magnitude as after otic ganglionectomy. 
 
3. Electrical stimulation of the facial nerve 
Stimulation of the peripheral facial nerve (40 Hz), divided at the level of the 
stylomastoid foramen, evoked a flow of saliva (1), in the presence of 
adrenoceptor blockade, that was about 10% of that in response to stimulation of 
the auriculo-temporal nerve (Månsson & Ekström, 1991). When preceded by otic 
ganglionectomy one week in advance, the facial nerve still evoked secretion 
albeit at a reduced rate, a response that was exaggerated due to 
supersensitivity.  Analytic pharmacology showed the facial nerve-evoked 
secretion to be unaffected by the ganglion blocker hexamethonium, but (almost) 
completely abolished by atropine. The facial secretory response was not due to 
electrical irradiation from the stimulating electrode, since a) firm ligation of the 
peripheral nerve stump distal to the electrode completely abolished the flow of 
saliva and further, (b) stimulation of the peripheral end of the facial nerve, divided 
7 days in advance, produced no flow of saliva from the gland. 
 
4. Stimulation of the great auricular nerve 
No support was gained for a secretory role for the great auricular nerve, since 
stimulation (40 Hz) of the nerve in innervated glands or sensitized glands, by otic 
ganglionectomy one week in advance, caused no flow of saliva (1).  
 
5. Further evidence for a facial nerve influence on the secretory cells 
Nerves exert long-term influences on the gland cells as revealed by the 
development of a postjunctional supersensitivity over a period of 2-3 weeks 
following parasympathetic or sympathetic denervation (Emmelin, 1965; Ekström, 
1980). However, no supersensitivity to the intravenous injection of methacholine 
was demonstrated 2-3 weeks following division of the facial nerve. Furthermore, 
no difference in the acetylcholine-synthesizing capacity existed between glands 
on operated and non-operated sides.  In contrast, one week postoperatively, the 
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parotid gland showed a slight sensitization to methacholine (as judged by the 
increase in volume response (25%) to a suprathreshold dose of this drug, a 
finding to be combined with the 15%-decrease in acetylcholine-synthesizing 
capacity of the gland on the operated side (1,2). For comparison, the secretory 
response to methacholine following otic ganglionectomy increased more than 
tenfold (I). The rapid restoration of the acetylcholine synthesizing capacity and 
the decrease in sensitivity may reflect compensatory impulse traffic in the 
remaining nerves and (or) collateral sprouting from these nerves (Ekström, 
1999b).  
 
6. Sensory contribution to the peptidergic gland innervation  
In the rat, vasoactive intestinal peptide is found in the otic ganglion but not in the 
trigeminal ganglion, whereas both calcitonin-gene related peptide and substance 
P are found in both the trigeminal ganglion and the otic ganglion (Ma et al., 2001; 
Hardebo et al., 1992). Almost all of the substance P- and vasoactive intestinal 
peptide-containing nerve fibres of the rat parotid gland reached the gland via the 
auriculo-temporal nerve trunk, while only a minor proportion of the calcitonin 
gene related peptide-containing nerve fibres did so (3): seven days after division 
of the auriculo-temporal nerve, the gland contents of vasoactive intestinal 
peptide, substance P and calcitonin gene related peptide were reduced by 88%, 
93% and 37%, respectively. Virtually all of the substance P- and vasoactive 
intestinal peptide-containing nerve fibres originated from the otic ganglion, while, 
once again, only a minor proportion of the calictonin gene related peptide-
containing nerve fibres was of otic origin: after otic ganglionectomy, the gland 
contents of substance P and vasoactive intestinal peptide were reduced by 98% 
and the gland content of calcitonin gene related peptide by 32%. No support for 
the idea that the auriculo-temporal nerve trunk supplied the gland with substance 
P- and/or calcitonin gene-related peptide-containing nerve fibres originating from 
another source than the otic ganglion was found: the division of the auriculo-
temporal nerve combined with otic ganglionectomy did not further lower the gland 
content of substance P (97%) and calcitonin gene related peptide (23%).  
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II. On the innervation of ferret salivary glands and their secretion: 
comparisons between glands, and with special focus on the submucosal 
zygomatic gland and the acetylcholine synthesis. 
 
1. Acetylcholine synthesis and Gland weights. 
(a) Intact glands  
Of the five types of glands studied the zygomatic and molar glands were heavier 
than the sublingual glands but lighter than the parotid and submandibular glands.  
The acetylcholine synthesis expressed per gland weight was three to four times 
higher in the mucin-producing sublingual, zygomatic and molar glands than in the 
serous parotid and seromucous submandibular glands (4).  
 
(b) Effects of division of the auriculo-temporal nerve and the buccal nerve  
Seven days postoperatively (4), the total amount of the acetylcholine-
synthesizing capacity was reduced by 97% in the parotid gland (auriculo-
temporal nerve), 95% in the zygomatic gland (buccal nerve) and 85% in the 
molar gland (buccal nerve). The parotid gland lost 15% in weight, while the 
weight loss was more pronounced in the zygomatic (46%) and molar glands 
(23%).  
 
2. Expression of muscarinic subtypes 
All five subtypes of muscarinic receptors were expressed in the five types of 
glands (4). The semiquantitative comparison within each gland showed the M3-
receptor subtype to dominate. The concentration of M5-receptor subtype was 
less in the mucinproducing glands than in the seous/sero-mucous glands. 
 
3. Secretory responses to nerve stimulation 
A resting viscous flow from the zygomatic gland was observed, while no resting 
secretion occurred from the parotid and submandibular glands (4). Expressed 
per gland weight, the parotid and submandibular glands secreted larger volumes 
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to stimulation of the auriculo-temporal nerve and chorda-lingual nerve, 
respectively, than the zygomatic gland to stimulation of the buccal nerve. A 
certain fraction of the secretory response of the zygomatic gland was due to 
mobilization of non-adrenergic, non-cholinergic transmitters, since in the 
presence of atropine (and α- and β-adrenoceptor blockers) 25% of the secretion 
persisted, to be compared with previous findings of the submandibular gland of 
30% and the parotid gland of 5% (Ekström et al., 1988b). 
 
4. Neuropeptides 
The three peptides vasoactive intestinal peptide, substance P and calcitonin 
gene related peptide were all present in the parotid, submandibular, zygomatic 
and molar glands, while the sublingual gland lacked detectable amounts of 
calcitonin gene-related peptide (4). Vasoactive intestinal peptide is associated 
with salivary protein secretion. However, no uniform pattern with respect to mucin 
producing and non-mucin producing glands was found; e.g.  the vasoactive 
intestinal peptide concentration was low both in the parotid gland and in the 
zygomatic gland.  
 
III. On the origin of acetylcholine and its specific synthesis 
 
The acetylcholine synthesizing capacity almost completely disappeared in the rat 
parotid gland in response to otic ganglionectomy (combined with division of the 
facial nerve) or to avulsion of the auriculo-temporal nerve (1), in the ferret parotid 
gland to avulsion of the auriculo-temporal nerve and in the ferret zygomatic gland 
to division of the buccal nerve (4). 
 
In salivary gland tissue extracts, the radioactive labeled acetylgroup is not only 
transferred to choline by the activity of choline acetyltransferase but also to 
carnitine by the activity of carnitine acetyltransferase (Banns & Ekström, 1981). 
Though the radioassay method of Fonnum (1975) is thought to avoid 
contamination of acetylcarnitine, comparisons between incubates where 
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acetylcholine is preserved (by physostigmine) and continuously destroyed (by 
cholinesterase) were always made (Banns et al., 1979). In incubates of 
innervated gland tissue extracts (of rat parotid gland and ferret parotid, 
submandibular, sublingual, zygomatic and molar glands) supplied with 
bromoacetylcholine, a specific inhibitor of choline acetyltransferase (Hendersson 
& Sastry, 1978), the enzyme activity was virtually abolished (95-99.5%). 
Likewise, the acetylcholine synthesis of the auriculo-temporal nerve (not 
containing carnitine acetyltransferase) showed a similar reduction in response to 
bromoacetylcholine (1, 4). In homogenates of denervated skeletal muscles a 
capacity to synthesize acetycholine of 5-8% is known to persist. In this case, 
bromoacetylcholine inhibited only 5% of the acetylcholine synthesis in the 
denervated muscle (Tuček, 1982). In contrast (1), and at the same concentration 
of bromoacetylcholine, the residual acetylcholine synthesizing capacity (2%) of 
the denervated rat parotid gland (otic ganglionectomy combined with section of 
the facial nerve) was reduced by 85% (20 nM), and at a higher concentration 
(200 nM) by 97%.  
 
Observations on humans 
 
IV. Healthy subjects: topical administration of physostigmine  
 
1. Secretion of saliva 
The volume response to all three doses of physostigmine (0.9 mg, 1.8 mg and 
3.6 mg), applied as spray, was increased, peak values being 1 ½ -2½ above 
basal level, while the response to placebo decreased over time (5). One hour 
and forty-five minutes after the administration the curves of placebo and of the 
various physostigmine doses met. Based on AUC-values (0-105 min), the 
response to 0.9 mg, 1.8 mg and 3.6 mg was elevated by 66%, 91% and 62% 
over placebo. Interestingly, that subject, which showed the largest basal 
secretion (three times that of the subject showing the second largest increase) 
did not show any increase to physostigmine. There is the possibility that an 
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existing film of saliva, covering the mucosa, may attenuate the uptake of 
physostigmine. Thus, the result of a physostigmine spray may be more effective 
in patients suffering from dry mouth.  
 
2. Safety results 
At the highest dose (7.2 mg) of physostigmine, two subjects complained of 
nausea and one of them discontinued the test. A third subject complained of a 
transient slight chest discomfort at 0.9 mg and 7.2 mg, but she experienced no 
respiratory distress. Neither blood pressure nor heart rate was affected over time 
by the three physostigmine doses. There were no complains in response to 
placebo. 
 
V. Salivary gland hypofunction: topical administration  of physostigmine 
 
In the first part of this study, the effect of various doses of physostigmine on the 
subjective feeling of dryness in the mouth or on the lips was estimated and 
reported or objectively noted signs of systemic effects were recorded (6). Based 
on safety results and relief in the feeling of dryness a dose of physostigmine was 
selected, to objectively estimate the effect on the volume of saliva in the second 
part of the study. 
 
1. Subjective assessment of dryness 
The baseline mean VAS scores for mouth dryness (“How do you feel in your 
mouth right now”) were not significantly different from each other in response to 
placebo and physostigmine at the dose levels of 0.9 mg, 1.8 mg, 3.6 mg and 7.2 
mg - varying between 75 and 68. The corresponding baseline VAS scores for lip 
dryness (“How do you feel on the inside of your lips right now”) were in the same 
range as those for mouth dryness - varying between 72 and 59. In response to 
physostigmine, the scores for both mouth and lips changed in tandem. 
Physostigmine at the dose levels of 0.9 mg, 1.8 mg and 3.6 mg caused 
significant and long-lasting relief in the feeling of dryness; placebo induced a 
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transient reduction in scores of about 5. In response to physostigmine, the 
reduction in scores was 10-15 at 0.9 mg (up to 120 min), about 25 at 1.8 mg (up 
to 120 min) and 15-20 at 3.6 mg (up to 180 min). The decrease in VAS scores 
was reflected in significant reductions in the area under the curve. When 
calculated over 180 min, as compared to placebo, the AUC-value at 
physostigmine 1.8 mg and 3.6 mg, respectively, was 6 and 5 times that of 
placebo. At the dose level of 7.2 mg of physostigmine, the subjects reported only 
a little relief from their dryness. Probably, the adverse effects that appeared at 
the higher doses (see below), distracted the subjects, thereby shifting their focus 
from oral sensations.  
 
2. Salivary secretion 
Following, placebo a small increase above baseline was initially (30 min) 
observed. In response to physostigmine 1.8 mg, elevated levels of secretion 
were found between 30 min and 180 min. The AUC values in response to 
physostigmine over 180 min was about five times that in response to placebo. 
 
3. Safety results 
In the first part of the study, no signs of systemic effects were recorded at the 
dose levels 0.9 mg and 1.8 mg. At 3.6 mg and 7.2 mg of physostigmine gastro-
intestinal disorders, mainly of mild character, were frequent. In the second part of 
the study, mild gastro-intestinal disorders were also reported to physostigmine 
1.8 mg. Most likely, the subjects were “primed” by the preceding tests, paying 
extra attention to the occurrence of anything unusual.  Placebo was in both parts 
of the study without systemic effects. Neither blood pressure nor heart rate were 
affected by the various doses of physostigmine.  
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General Discussion 
 
Textbooks usually depict the parasympathetic secretory nerve fibres of the 
parotid gland, arising from the inferior salivatory nucleus, to travel via the 
tympanic branch of the glossopharyngeal nerve (Jacobson´s nerve), the 
tympanic plexus, the small superficial petrosal nerve and, after relaying in the otic 
ganglion, the auriculo-temporal nerve to reach the gland cells (Bradley, 1995; 
Ferguson, 1999), a concept originating from early observations in the dog (see 
Holmberg, 1972).  
 
The nerve routes of the parotid gland seem, however, to be more complex than 
outlined above. The human parotid gland is supplied not only by fibres of the 
glossopharyngeal nerve but also by fibres of the chorda tympani branch of the 
facial nerve, since reflex parotid secretion is affected not only by the division of 
the glossopharyngeal nerve intracranially but also by the division of the chorda 
tympani in the tympanic membrane (Reichert & Poth, 1933; Diamant  & Wiberg, 
1965). In the rat, there is no direct connection with the glossopharyngeal nerve 
and the otic ganglion; the tympanic branch of the glossopharyngeal nerve does 
not exist (Contreras et al., 1980; Al-Hadithi & Mitchell, 1987). The only visible 
connection between the otic ganglion and the cranial nerves seems to be a 
branch of the facial nerve. A further connection between the facial nerve and the 
glossopharyngeal nerve has also been described in this species, which 
tentatively may offer a passage for salivatory preganglionic axons from the IXth 
nerve to the VIIth nerve (Al-Hadithi & Mitchell, 1987). In the dog (Emmelin et al., 
1968) as well as in the cat (Ekström & Emmelin, 1974a,b), reflexly elicited 
secretion is still obtained, albeit markedly reduced,  from the parotid gland after 
division of the auriculo-temporal nerve - not depending on the sympathetic 
innervation and blockable by atropine -  showing that cholinergic nerve fibres 
outside the auriculo-temporal nerve innervate the gland. Extensive studies by 
Holmberg (1971, 1972) showed cholinergic nerve fibres, detached at an early 
stage from the auriculo-temporal nerve, to reach the gland via the internal 
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maxillary artery, a finding later also observed in the cat (Ekström & Emmelin, 
1974b).   The present Thesis, using the rat as experimental animal, focused on 
the otic ganglion and yet another peripheral secretory pathway: the facial nerve.  
 
The history of salivary glands and nerves began with the discovery of Carl 
Ludwig in 1850, when he described that electrical stimulation of the chorda-
lingual nerve caused a copious flow of submandibular saliva in the dog (Garrett, 
1999). In submandibular glands, relays between pre- and postganglionic nerve 
fibres occur intraglandularly. Apart from a recent study concerned with the 
influence of sympathectomy on the neuropeptide content of the parotid gland of 
the rat (Ekström & Ekman, 2005), the effect of otic ganglionectomy on the parotid 
gland innervation has not previously been reported.  The otic ganglion in the rat 
is a discoid structure of about 1 mm in diameter located in the foramen ovale. It 
lies medial to the pterygopalantine branch of the internal carotid artery 
(corresponding to the pterygopalatine portion of the internal maxillary branch of 
the external carotid artery in man) and is separated from the trigeminal ganglion 
by the sphenoid bone (Al-Hadithi & Mitchell, 1987). Otic ganglionectomy affected 
the parotid gland more profoundly than division of the auriculo-temporal nerve 
with respect to loss in gland weight, synthesis of acetylcholine and reflex 
secretion (1); the latter was, in fact, almost abolished (in the presence of α- and 
β-adrenoceptor blockade). As judged from the acetylcholine synthesis, the 
proportion of cholinergic nerve fibres to the parotid gland outside the auriculo-
temporal nerve is about the same in the rat  (24%) and the dog (29%, Ekström & 
Holmberg, 1972) but lower in the cat (11%, Ekström & Emmelin, 1974b). In the 
present investigation, no attempt was made to trace nerve fibres on the artery to 
the gland. Since otic ganglionectomy combined with division of the facial nerve 
reduced the acetylcholine synthesis of the parotid gland even more than division 
of the auriculo-temporal nerve combined with division of the facial nerve, a 
minute contribution seems to occur by additional routes to the parotid gland in 
the rat. The great auricular nerve was not such a route as to the cholinergic 
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innervation (1). Neither is the sympathetic innervation a route for cholinergic 
nerves to the gland (Ekström, 1972). 
 
The facial nerve (1,2) contributed to the acetylcholine synthesizing capacity of 
the three lobes of the gland, evoked secretion upon electrical stimulation (about 
10% of that to stimulation of the auriculo-temporal nerve), conveyed reflexly 
elicited impulses for secretion, via the otic ganglion, and exerted trophic effects 
on the secretory cells (as shown by the development of denervation 
supersensitivity). The secretion was of cholinergic muscarinic nature and the 
secretory nerve fibres originated mainly from the otic ganglion. However, the 
present findings did also suggest that some parasympathetic cholinergic nerve 
fibres relayed outside the otic ganglion, since after otic ganglionectomy,  the 
facial nerve still contributed to a certain fraction of the acetylcholine synthesis of 
the gland and the stimulation of the facial nerve still evoked a small secretory 
response (blockable by atropine). It cannot be excluded that some facial somato-
motor fibres contributed to the residual acetylcholine synthesis. However, the 
even distribution of the facial nerve in the gland, as judged by the contribution of 
the facial nerve to the acetylcholine synthesis of the three lobes of the gland 
seems to favour the idea that somato-motor fibres, escaping dissection, 
contribute but little to the acetylcholine synthesis of the gland. There is not 
necessarily a direct relationship between the acetylcholine synthesizing capacity 
of the gland and its cholinergic innervation stimulating to fluid secretion. 
Cholinergic nerve fibres supply vessels, myoepithelial cells and ducts in addition 
to the secretory acinar cells (Garrett, 1999). The location of the extra-otic relay 
between pre- and postganglionic nerves was not located in the facial nerve distal 
to the level of the stylomastoid foramen.  Moreover, the parotid gland is known to 
lack ganglia (Garrett, 1999). Where fibres to innervate the parotid gland join the 
facial nerve, if they do not originate from the nerve itself, is presently unknown. A 
secretory role for the facial nerve in the parotid gland may be a general 
phenomenon among the various species. In the dog, the facial nerve contributes 
to a small proportion of the acetylcholine synthesizing capacity of the gland and 
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to a minute cholinergic secretory response (Ekström & Holmberg, 1972). A brief 
report states that in cats the facial nerve trunk (at the level of the stylomastoid 
foramen) carries impulses evoking secretion from the parotid gland evoked by 
stimulation of the inferior salivatory nucleus (Porto et al., 1981). In humans 
suffering from unilateral facial nerve paresis, parotid secretion on the parethetic 
side upon reflex secretion is reduced (Vollrath et al., 1980).  
 
The denervation technique applied was evidently of importance not only with 
respect to the inclusion of various pathways but also whether the approach of 
avulsion or cutting the respective nerve was chosen. Avulsion of a nerve is likely 
to cause more damage than just cutting the nerve (1,4). Avulsion of the auriculo-
temporal nerve was more effective than otic ganglionectomy with respect to the 
decrease in the acetylcholine synthesizing capacity in the gland (99% versus 
88%) and as effective as otic ganglionectomy with respect to abolishing reflex 
secretion (99% versus 98%). Avulsion of the auriculo-temporal nerve was also 
used to denervate the rabbit parotid gland (Nordenfelt, 1964) and presently, the 
ferret parotid gland, and also here, the acetylcholine synthesis was almost 
abolished  (97% and 96%, respectively). 
 
Regenerating cholinergic nerve fibres of an intentionally or unintentionally 
damaged auriculo-temporal nerve are no doubt the main cause to the re-
innervation of the sympathetically denervated sweat glands and skin vessels 
(normally under the influence of a cholinergic transmission mechanism and 
possible, peptidergic transmission mechanisms such as that using vasoactive 
intestinal peptide, Drummond, 2002) and, consequently, the development of 
gustatory sweating and flushing (Glaister et al., 1958; Dunbar et al., 2002; 
Tugnolgi et al., 2002). Regenerating cholinergic somato-motor nerve fibres only 
exceptionally establish functional contact with salivary gland cells (Emmelin et 
al., 1960). With the present knowledge of a facial nerve that carries secretory 
parasympathetic nerve fibres to the parotid gland (1,2), a damaged facial nerve 
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may be regarded as a potential contributor to the development of Frey´s 
syndrome.  
 
Loss of most of the cholinergic innervation of the parotid gland, by division of the 
auriculo-temporal, is followed by a gradual restoration of the acetylcholine 
synthesizing capacity and a gradual fall in the level of sensitivity of the secretory 
cells of the parotid gland over several months and concomitant with increased 
reflex responses, as shown in the cat (Ekström & Emmelin, 1974a). In the 
present Thesis, the decrease in the acetylcholine synthesizing capacity and the 
slight increase in the sensitivity to methacholine in the parotid gland, following the 
division of the facial nerve, were very short-lasting events and might easily go 
unnoticed (2).  Similar transient changes in the level of sensitivity and 
acetylcholine synthesizing capacity occur in the partially denervated urinary 
bladder and further, the persisting cholinergic axons of the sprout (Alm & 
Ekström, 1981). Collateral sprouting from the fibres of the auriculo-temporal 
nerve and increased traffic of impulses in that nerve are likely causes to the rapid 
recovery after damage to the facial nerve.  
 
The sensory periductal and perivascular nerve fibres of salivary glands, 
containing both substance P and calcitonin gene related peptide, disappear in 
response to capsaicin treatment showing that these fibres are of sensory origin 
(Ekström et al., 1988a, 1989). The gland contents of substance P and calcitonin 
gene-related peptide are reduced by the capsaicin treatment, by 11% and 36%, 
respectively. For comparison, the same capsaicin treatment reduces the contents 
of substance P and calcitonin gene related peptide by 90% in the urinary bladder 
(Ekström & Ekman, 2005). A likely origin of these fibres is the trigeminal 
ganglion. In this ganglion, the two peptides are co-localized but, in addition, 
calcitonin gene related peptide occurs in neurons of the Aδ-fiber type, devoid of 
substance P (Ma et al., 2001), and not likely to be sensitive to capsaicin. Thus, 
there is the possibility that also capsaicin-nonsensitive sensory nerves exist in 
salivary glands. Moreover, capsaicin-nonsensitive effector responses can be 
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elicited by the electrical stimulation of the trigeminal ganglion as shown by 
menigeal vasodilatation (Peitl et al., 1999). Tentatively, the sensory nerves of 
salivary glands may exert protective functions by mobilizing defensive agents of 
the ductal cells, e.g. β-defensins (Darnell et al., 2006), or they may stimulate the 
myopithelial cells to increase the intra-ductal pressure to overcome distension of 
the duct-system or to eject noxious substances. Interestingly, the substance P-
relative non-mammalian tachykinin physalaemin contracts the myoepithelial cells 
(Thulin, 1976b). The perivascular localization may suggest that they may be 
associated with the inflammatory response. Both substance P and calcitonin 
gene-related peptide are involved in protein extravasation and oedema formation 
in the salivary glands (Asztély et al., 1998). In recent years, neurogenic 
inflammation has come into focus, e.g. in connection with asthma (Barnes et al., 
1990). The afferent sensory nerves are thought to exert efferent functions 
through local axonal reflexes and may maintain and prolong the inflammatory 
response.  Hypothetically, sensory nerves may be involved in chronic salivary 
gland inflammation. Moreover, they may be involved in the postsympathectomy 
pain in the parotid gland upon eating (Schon, 1985).  
 
Evidently, the trigeminal ganglion did not seem to contribute with substance P 
and calcitonin gene-related peptide via the auriculo-temporal nerve trunk (3). A 
previous report (Sharkey & Templeton, 1984), showed that a portion of True Blue 
retrogradely labeled nerve cell bodies of the trigeminal ganglion, following 
injection of the dye in the rat parotid gland, contained immunoreactivity for 
substance P. This made the authors to conclude that substance P-containing 
neurons of the trigeminal ganglion innervate the parotid gland via the auriculo-
temporal nerve trunk; however, compelling evidence for the auriculo-temporal 
pathway was not presented. Unfortunately, the dye was not injected in the 
parotid gland subjected to division of the auriculo-temporal nerve in advance to 
verify the auriculo-temporal nerve as the route for those neurons of the trigeminal 
ganglion that contained substance P. The great auricular nerve, like the facial 
nerve, penetrates the parotid gland (Zohar et al., 2002), and both nerves are 
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likely pathways for both substance P and calcitonin gene realated peptide as 
shown in denervation experiments (Ekström et al., 1988a). The great auricular 
nerve does also supply the parotid fascia (Zohar et al., 2002).  Stretching of the 
fascial layer encapsulating the glands, as for instance in response to gland 
swelling, is thought to give rise to pain (Shapiro 1973; Leipzig & Obert, 1979). A 
large number of calcitonin gene-related peptide-containing nerve fibres is 
presently not accounted for. They do not reach the gland via the sympathetic 
innervation (Ekström et al., 1988a).  
  
The zygomatic gland, located in a space in the anterio-lateral part of the soft 
palate in the infratemporal fossa less than one mm beneath the mucosa, is a well 
defined gland with two ducts opening on the mucosal ridge posterio-medial to the 
parotid gland. The lateral duct drains 80% of the gland and is easily accessible 
for cannulation (Shackleford & Wilborn, 1968; Ekström & Helander, 2002). 
Likewise, the molar gland, located opposite the lower molar teeth, is well defined 
but less in size and with several excretory ducts, emptying in relation to the same 
teeth. The zygomatic gland of the ferret (4) was found to be yet another gland to 
be added to the list of salivary glands that respond with a flow of saliva upon 
stimulation of the parasympathetic nerve in the presence of atropine (and 
adrenoceptor blockers). The concentrations of the neuropeptides in the five types 
of glands did not reveal any conspicuous pattern with respect to mucous glands 
versus serous/seromucous glands. Though, the muscarinic receptor subtype M1 
usually is thought to be associated with mucous cells (Watson & Culp, 1994), no 
preponderance for the expression of the M1 receptor type in the mucous glands 
was found in the ferret glands. In fact, immunochemistry of the major human 
salivary glands shows the M1 receptor type to be confined to the serous cells 
and not to the mucous cells (Ekström, Helander, Godoy, Grunditz and Riva, to be 
published).  
 
Apart from an early observation of the sublingual gland of the rat, the 
acetylcholine synthesis of mucous glands does not seem to have been studied 
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previously. In the rat, the acetylcholine synthesis, expressed in terms of 
concentration, was comparable to that of the parotid gland but higher than that of 
the submandibular gland (Ekström, 1972). Comparisons with respect to the 
acetylcholine synthesis, expressed as concentration, revealed a striking 
difference in the ferret between, on one hand, the mucous sublingual, zygomatic 
and molar glands and, on the other hand, the serous parotid gland and the 
seromucous submandibular gland, since the acetylcholine synthesis (per unit 
weight) was  3-4 times greater in the mucin-producing glands than in the parotid 
and submandibular glands (4). The zygomatic gland of the anaesthetized ferret, 
as also shown in the cat (Al-Gailani et al., 1981), was found to secrete 
continuously at a low rate. At first sight this continuous secretion may be thought 
to be associated with the high acetylcholine synthesis. However, the resting 
secretion persists in the presence of atropine (Ekström & Helander, 2002).  No 
support for the idea of an extra-neuronal glandular synthesis of acetylcholine of 
any significance was found in the glands, and this was regardless of whether the 
acetylcholine synthesis was high or low. Division of the buccal nerve, a branch of 
the mandibular nerve and thought to originate from the otic ganglion (Kuchiiwa & 
Kuchiiwa, 1996), reduced the acetylcholine synthesis (expressed per gland) by 
95%, while avulsion of the auriculo-temporal nerve reduced the synthesis by 96% 
in the parotid gland. In analogy with the rat parotid gland (see above) nerves may 
escape the denervation procedure. With respect to the molar gland, this gland 
seems to have a dual innervation, the buccal nerve and, in addition, the 
mylohyoid nerve (Kuchiiwa & Kuchiiwa, 1996); in the molar gland the 
acetylcholine synthesis decreased by 85% in response to the division of the 
buccal nerve. The high acetylcholine synthesis, in terms of concentration, in the 
sublingual, zygomatic and molar glands is thought to reflect a high reflexly 
elicited parasympathetic tone over time. The fact that the parasympathetic 
postganglionic denervation of the zygomatic gland caused a much more 
pronounced fall in weight than that of the parotid gland supports such an 
assumption. Presently, nothing is known about the acetylcholine synthesizing 
capacity of human salivary glands. 
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In humans, several hundreds of minor glands are found in the mouth and named 
after their location, i.e., lingual, labial, buccal, palatinal, pharyngeal and uvulal 
glands. Only the gingiva and the midline and anterior part of the hard palate lack 
the minor glands. The glands are located in the submucosa surrounded by 
connective tissue or muscle fibres. In contrast to the major glands, the minor 
glands are not encased in a fibrous capsule.  Apart from the posterior deep 
lingual gland (von Ebner´s), the minor human salivary glands are mucous in 
character but do also, to varying extent, contain seromucous cells usually 
capping the end of mucous acini and tubules (Hand et al., 1999; Riva et al., 
1999). Secretory cells, classified as seromucous, show a cell morphology 
intermediate between true serous cells and mucous cells; the seromucous cells 
have granules with low electron density. Interestingly, the seromucous cells have 
been suggested to reflect maturative stages of mucous cells (Riva et al., 1999). 
The minor glands are located just under the mucosal epithelium. The ductal 
system is less well-developed as compared to those of the major gland. The 
excretory duct of individual glands open directly onto the mucosa. The saliva 
produced, is likely to be responsible for the local environment of the mucosal 
surface. The buccal and lingual glands display the highest salivary flow rate, the 
labial gland an intermediate and the palatal gland the lowest flow rate (calculated 
per area of mucosal surface per min) (Riva et al., 1999). As judged by the labial 
glands, the salivary secretion from minor glands in humans can be evoked 
reflexly by strong gustatory stimulants and mechanical stimulations such as 
chewing and speaking (Speirs, 1984; Gandara et al., 1985; Boros et al., 1999). 
The acinar cells of the labial glands are not only innervated by cholinergic nerves 
(Rossini et al., 1979) but also by vasoactive intestinal peptide-containing nerves 
(Fehér et al., 1999); the acinar cells lack adrenergic innervation (Rossini et al., 
1979).  Local application of physostigmine evokes secretion from labial glands 
(Hedner et al., 2001) and further, isolated pieces of labial glands respond to 
muscarinic agonists but poorly to adrenergic receptor agonists (Turner et al., 
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1999). The contribution of the minor glands to the whole amount of saliva 
produced is calculated to 7-8% (Dawes & Wood, 1973) 
 
Saliva forms a thin film that coats the oral structures. Marked regional differences 
in the thickness of the fluid layer on the oral mucosa exist, the highest figure (70 
µm) is from the posterior dorsum of the tongue and the lowest figure (10 µm) is 
from the hard palate (DiSabato-Mordaski & Kleinberg, 1996; Wolff & Kleinberg, 
1998). The volume of saliva in the oral cavity is not only depending on the 
secretion of saliva but also of evaporation, absorption through the oral mucosa 
and swallowing. Evaporative loss of fluid is mainly due to mouth breathing and 
speaking. The hard palate with its thin fluid layer will be particularly exposed to 
the effect of evaporation, since it is directly exposed to the flow of inspired air 
(Thelin et al., 2008). The oral mucosa is permeable for water. Movement of water 
across the oral mucosa occurs due to an osmotic gradient (resting saliva being 
hypotonic) and to an active ion transport of sodium. Under normal conditions, the 
volume of saliva entering the mouth exceeds the loss of volume by evaporation 
and absorption. Excess of saliva initiates a swallowing reflex. The volume that is 
swallowed amounts to about 0.3 ml per swallow (Lagerlöf & Dawes, 1984).  
 
Though the figure for a mean flow rate of resting whole saliva is about 0.3 ml per 
min in healthy subjects (Dawes, 1987), large inter-individual differences exist 
without complains of xerostomia:  from 0.008 to 1.85 ml per min in one study 
(Becks & Wainwright, 1943) and from 0.25 to 5.58 ml per min in another study 
(Heintze et al., 1983), and also illustrated in the present Thesis.  Xerostomia is 
not a reliable predictor of salivary gland hypofunction. In large study groups, 
where all subjects complained of xerostomia, only 54-58% of them showed low 
flow rates (Field et al., 1997; Longman et al., 1995). Despite wide differences 
between healthy subjects in resting secretion, a parasympatholytic-induced 
decrease by about 50% of an individual’s resting secretion gives rise to the 
feeling of oral dryness (Dawes, 1987; Wolff & Kleinberg, 1999). Under this 
circumstance, the thickness of the saliva film of the anterior dorsum of the tongue 
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and the hard palate is less than 10 µm, and from these locations the subjects 
experience the most pronounced symptoms of xerostomia (Wolff & Kleinberg, 
1999).  Interestingly, a decrease in the labial fluid output of 21% is correlated to 
the feeling of dryness (Eliasson et al., 1996). 
 
Physostigmine was locally applied onto the non-keratinized mucosa (5,6), which 
is permeable for drugs, and in a region where the density of minor glands is high: 
in a spray formulation onto the inside of the lower lip and the buccal mucosa in 
healthy subjects or in a gel formulation onto the inside of the lower and upper lip 
and then, distributed in the mouth with the tongue. The amount of saliva collected 
was in both types of experiments elevated over a relatively long period of time (in 
response to the same dose level), 90-120 min. In the group of subjects showing 
salivary gland hypofunction, the secretion was about twice that of baseline during 
the first 60 min. In these dry mouth-patients, the mean AUC-value for the volume 
response over 180 min to physostigmine was five times higher than that to 
placebo.  
 
It cannot be excluded that the “grapefruit-like” taste of the drug gave rise to a 
certain reflex secretion initially, as reflected by the placebo-response. In addition, 
a transient osmotic attraction of fluid from the interstitium of the mucosa to the 
mucosal surface may have occurred, since in animal experiments, using the 
ferret as model, the osmolality of both the placebo and the physostigmine 
solutions is higher than in the body fluids (Ekström & Helander, 2002).  
 
The local application of physostigmine in humans aimed at selectively activating 
the underlying submucosal minor glands to secretion of saliva, while at the same 
time cholinergic systemic effects would be avoided or minimized (5,6). Support 
for the assumption that physostigmine acts locally by diffusing through the 
mucosal barrier and causing secretion without systemic effects was initially 
gained from observations in the ferret (Ekström & Helander, 2002). In this 
preparation, the flow of saliva from the parotid, submandibular and sublingual 
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glands, on both sides, was diverted from the mouth. Local application of 
physostigmine on the buccal and labial mucosa on one side increased the 
amount of saliva on the exposed side but not on the contralateral side. Likewise, 
by duct-cannulation of the zygomatic gland, an increase in the resting flow rate of 
saliva was revealed in response to physostigmine applied on the overlying 
mucosa but no increase in the flow rate of saliva from the contralateral gland 
occurred. Moreover, there was no secretion from duct-cannulated parotid and 
submandibular glands providing further evidence for a local effect of 
physostigmine. The increase in secretory rate to physostigmine did not involve 
central mechanisms. It was due to a muscarinic action on the secretory cells.  
However, by increasing the concentration of the locally applied physostigmine a 
small secretory response of the contralateral side (and the contralateral 
zygomatic gland) as well as from the duct-cannulated major glands occurred, 
blockable by atropine, signalling systemic cholinergic effects. Subsequently, a 
direct evidence for local activation of labial glands in humans was provided by 
the topical application of physostigmine on an overlying small mucosal area 
(Hedner et al., 2001).  
 
In analogy, the secretion of saliva in response to physostigmine in the present 
studies is assumed to be preferentially due to the local action of physostigmine, 
by causing acetylcholine to accumulate in the neuro-glandular junction. The rigid 
protocol presently applied in the human studies did, unfortunately not, include the 
possibility to consider a systemic physostigmine- induced secretory contribution, 
for instance, by applying the Lashley-Crittenden cup over the orifice of the parotid 
gland to record the flow of saliva, if any, in a separate set of tests. The fact that 
systemic side effects, such as gastro-intestinal discomfort, appeared in respone 
to increasing doses of physostigmine shows that physostigmine reaches the 
circulation. 
 
Though, certain drawbacks with the use of the Visual Analogue Scale to score 
the feeling of dryness and the possible relief in response to physostigmine, such 
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as not applying the scale at the screening process, not exposing all subjects to 
placebo, not allowing the subjects to see their immediate preceding score and 
difficulties in compliance, a significant effect of physostigmine was revealed (6). 
Intra-individual comparisons (with baseline before administration of 
physostigmine) showed long-lasting decreases in the feeling of dryness with 
respect to the lips and the whole mouth for up to 120-180 min, the reduction in 
scores being 25% to a dose of physostigmine of 1.8 mg, i.e the same dose level 
that was used for the objective measurement of the saliva secreted (see above). 
According to mean AUC value (over 180 min), the improvement was six times 
greater than that produced by placebo at this dose level. Though, the volume 
responses, to higher doses, of physostigmine are expected to increase, the relief 
in oral dryness, as judged by the Visual Analogue Scale, decreased instead. This 
inverse response at higher doses is probably due to the fact that feelings 
associated with side effects, such as nausea, got the upper hand and shifted the 
focus from oral sensations. The overwhelming type of systemic side-effects of 
the drug, in the doses tested, was gastro-intestinal discomfort, usually classified 
as mild to moderate. Compared to muscarinic receptor agonists on the market for 
systemic treatment of dry mouth, the frequency of side-effects is less with the 
local administration of physostigmine presently tested (Wiseman & Faulds, 1995;  
Wynn et al., 2004). The therapeutic window for physostigmine, in its present 
formulation, may seem narrow as for all drugs with cholinergic effects.  
 
The long duration of the effect of a single dose of physostigmine in terms of the 
secretion of saliva and the relief of the feeling of dryness was surprising, since 
the half-life of the drug is 15-30 min in plasma (Nordberg & Svensson, 1998). It is 
presently not known whether the long-lasting effect is due to the drug being 
retained in oral tissues, including the glands. Interindividually, large variations 
exist with respect to the pharmacokinetics of physostigmine (Sharpless & Thal, 
1985; Thal et al., 1986; Hartwig et al., 1990; Asthana et al., 1995). Physostigmine 
levels, the volume of distribution, and the clearance may vary threefold between 
patients receiving identical intravenous doses. The bioavailibilty of the drug after 
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swallowing (Nordberg & Svensson, 1998; Hartwig et al., 1990) is usually 
considered low (<10%), but higher values have been reported (23%).  The local 
treatment of dry mouth with physostigmine, as explored in this Thesis, is a novel 
approach that may turn out to be a therapeutic option. Since subjects may be 
more or less sensitive to the local application of physostigmine with respect to 
secretion and adverse effects based on pharmacokinetic causes, both the dose 
and the interval of administration may need to be individualized.  
 
   
Main Conclusions 
 
Almost all of the parotid cholinergic innervation in the rat is derived from the otic 
ganglion. Cholinergic nerve fibres from the ganglion reach the gland not only via 
the auriculo-temporal nerve but also via the facial nerve and, in addition, some 
other route(s). The reflexly elicited cholinergic (as well as the non-adrenergic, 
non-cholinergic) secretion is relayed via the otic ganglion.  
 
The facial nerve supplies the parotid gland with cholinergic secreto-motor fibres 
and takes part in the reflex secretion.The nerve exerts a trophic influence on the 
secretory cells of the parotid gland. It is a potential contributor to the 
development of Frey´s syndrome. 
 
Almost all substance P-containing nerve fibres innervating the parotid gland 
originate from the otic ganglion in the rat. Only a minor part of the calcitonin 
gene-related peptide-innervation of the gland is derived from the otic ganglion. 
The trigeminal ganglion does not contribute to the sensory substance P- and 
calcitonin gene-related peptide-innervation of the parotid gland via the auriculo-
temporal nerve trunk.   
 
The acetylcholine synthesis, expressed per gland weight, was three to four times 
higher in the mucin-producing sublingual, zygomatic and molar glands than in the 
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serous parotid and sero-mucous submandibular glands in the ferret. The high 
acetylcholine synthesizing capacity in the mucous glands reflects a high 
cholinergic tone over time. Muscarinic receptor subtypes M1-M5 were detected in 
all five glands but there was no preponderance for M1-subtype in the mucin-
producing glands. A part of the parasympathetic secretory response of the 
zygomatic gland depended on non-adrenergic, non-cholinergic transmission 
mechanisms probably involving substance P and vasoactive intestinal peptide 
and possibly calcitonin gene-related peptide. 
 
The activity of choline acetyltransferase was responsible for the acetylcholine 
synthesis in the glands. Denervation experiments showed virtually all of the 
acetylcholine synthesis, due to the activity of choline acetyltransferase, to be of 
nervous origin (and not of non-nervous origin). 
 
The cholinesterase inhibitor physostigmine topically applied on the oral mucosa 
evoked a long-lasting secretion of saliva in healthy subjects and in patients 
suffering from salivary gland hypofunction. A long-lasting relief in the patients 
suffering from dry mouth was revealed by the use of a Visual Analogue Scale. It 
was possible to find a dose of physostigmine that both objectively and 
subjectively was of effect with cholinergic systemic effects at a minimum, if any. 
Local treatment aiming at activating hundreds of minor salivary glands, situated 
just below the oral epithelium, to secrete, while at the same time minimising 
systemic side-effects is a novel and promising approach to the treatment of dry 
mouth. 
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